RE:price being completely controlled held down.Yes- I too found the comment "we are now running both companies for almost 10% less than the cost of running MediPharm stand-alone in 2022" interesting. Despite numerous opinions to the contrary it shows Management is managing to revenue well. Been accumulating slowly since 2022 and do have some frustration with the lost opportunity cost- however in my hymble opinion stock is consoldating at the bottom. I also believe it is manipulated-which is eary to do with penny stocks with low volume. Overall I do think this will move with a few more Cannibis catalyst and who knows- a buy out may make sense when the market cap runs up. Meanwhile my hope-allbeit NOT a Strategy- is Drabiol will solidiy consistent revenue-which is very much needed. From there the SP has got to move.
GLTA